We are live on ! Find out more
MTRI icon

Mentari Therapeutics, Inc. Common Stock

4 hedge funds and large institutions have $2.99M invested in Mentari Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more capital inflows, than outflows

Capital inflows: $2.09M | Capital outflows: $667K

5.94% more ownership

Funds ownership: 5.8% → 11.74% (+5.9%)

43% less funds holding

Funds holding: 7 → 4 (-3)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
4
Holders Change
-3
Holders Change %
-42.86%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

MTRI Hedge Fund Activity: Q2 2021 in Review

4 of the 5,771 institutional investors tracked by Wall St. Rank reported a position in Mentari Therapeutics, Inc. Common Stock (MTRI) for Q2 2021, worth a combined $2.99M — up 93% from $1.55M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of MTRI and 1 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Armistice Capital, adding an estimated $2.03M. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $531K sold.

  • 4 institutional investors held Mentari Therapeutics, Inc. Common Stock (MTRI) as of Q2 2021, down from 7 in Q1 2021.
  • Funds reported $2.99M of Mentari Therapeutics, Inc. Common Stock stock for Q2 2021, up 93% quarter-over-quarter.
  • 1 fund opened new Mentari Therapeutics, Inc. Common Stock positions in Q2 2021 and 4 closed out, a net change of -3 holders.
  • The largest Mentari Therapeutics, Inc. Common Stock buyer in Q2 2021 was Armistice Capital, an estimated $2.03M added.
  • The largest Mentari Therapeutics, Inc. Common Stock seller in Q2 2021 was Hudson Bay Capital Management, an estimated $531K sold.

Based on aggregated 13F filings for Q2 2021.